Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Pemetrexed in Second Line Advanced/Metastatic Osteosarcomas

NCT00523419 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT00523419
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00523419 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Pemetrexed in Second Line Advanced/Metastatic Osteosarcomas
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2007
Completion date
June 30, 2010
Enrollment
32 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

osteosarcoma